טוען...
Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment
Gepotidacin is a novel triazaacenaphthylene bacterial topoisomerase inhibitor. This phase 1 nonrandomized, open‐label, multicenter, 2‐part study evaluated the pharmacokinetics, safety, and tolerability of oral gepotidacin 1500 mg in 3 different hepatic settings (normal, moderate impairment, and seve...
שמור ב:
| הוצא לאור ב: | Clin Pharmacol Drug Dev |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8248074/ https://ncbi.nlm.nih.gov/pubmed/33450142 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.913 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|